Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy.
Read Next
- NVIDIA’s Grace and Grace Hopper CPUs Propel Ansys Workloads to New Heights
- Bluesky CEO Jay Graber says X rival is ‘billionaire proof’
- Trump AG pick Matt Gaetz says he’s withdrawing
- Italy’s CONSOB issues orders for blocking of access to five unauthorised investment websites
- Will create 4 million women in the workforce over the next three years: FICCI President, ET BFSI
- Alphabet shares slide 6% following DOJ push for Google to divest Chrome
- Revolutionizing Customer Service: AI Agents Enhance Efficiency and Personalization